Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 20 of the 31 sources its claims cite were checked for support.

Targeting transcription factors through an IMiD independent zinc finger domain

Open access

Published version of a preprint

Abstract

Immunomodulatory imide drugs (IMiDs) degrade specific C2H2 zinc finger degrons in transcription factors, making them effective against certain cancers. SALL4, a cancer driver, contains seven C2H2 zinc fingers in three clusters, including an IMiD degron in zinc finger cluster one (ZFC1). Surprisingly, IMiDs do not inhibit the growth of SALL4-expressing cancer cells. To overcome this limit, we focused on a non-IMiD domain, SALL4 zinc finger cluster four (ZFC4). By combining ZFC4-DNA crystal structure and an in silico docking algorithm, in conjunction with cell viability assays, we screened several chemical libraries against a potentially druggable binding pocket, leading to the discovery of SH6, a compound that selectively targets SALL4-expressing cancer cells. Mechanistic studies revealed that SH6 degrades SALL4 protein through the CUL4A/CRBN pathway, while deletion of ZFC4 abolished this activity. Moreover, SH6 treatment led to a significant 87% tumor growth inhibition of SALL4+ patient-derived xenografts and demonstrated good bioavailability in pharmacokinetic studies. In summary, these studies represent a new approach for IMiD independent drug discovery targeting C2H2 transcription factors such as SALL4 in cancer.

Overview

CoChat Summary

## TL;DR

The paper identifies SH6 as a small molecule that targets the ZFC4 zinc-finger domain of SALL4, degrading both SALL4 isoforms through the CUL4A/CRBN pathway and selectively killing SALL4-expressing cancer cells. In mouse models, SH6 reduced tumor growth by 87% in patient-derived xenografts and showed favorable pharmacokinetic and tolerability profiles.

## Key findings

  • The authors solved the SALL4 ZFC4–DNA crystal structure at 2.1 Å and used this plus AlphaFold2-based modeling to find a druggable pocket shared by SALL4A and SALL4B.
  • Screening 676 compounds yielded 119 with docking scores below −5.0; SH6 was selected as the lead because it showed the best overall potency/permeability profile.
  • In cell assays, SH6 selectively killed SALL4-high cancer cells, with EC50 values of 0.5 μM in SNU398 and 0.21–1.30 μM in other SALL4-high lines, versus >10 μM in SALL4-low SNU387 cells and >25 μM in non-transformed THLE2/THLE3 cells.
  • In a patient-derived xenograft from a 72-year-old male HCC patient, SH6 produced 87% tumor growth inhibition; mean tumor volume was 1495 ± 104.5 mm³ in controls versus 186.3 ± 16.4 mm³ with SH6.
  • SH6 showed favorable drug-like properties, including 63.6% oral bioavailability, 1.67 h half-life in mice, and hERG blockade only at 22.2 μM.

## Methods

  • Structural work: the team purified SALL4 ZFC4, co-crystallized it with a 12-bp DNA duplex, solved the structure by crystallography, and generated SALL4A/SALL4B models with AlphaFold2 for pocket prediction and docking.
  • Screening and validation: 676 compounds from known and in-house libraries were docked to predicted sites, then tested in cell-based phenotypic screens in SALL4-high, SALL4-low, and isogenic SALL4A/SALL4B-overexpressing cell lines.
  • Mechanism and in vivo studies: they used western blotting, CETSA, SPR, dual-luciferase/Nanoluc assays, mass spectrometry, xenograft mouse studies, and a PDX model to test target engagement, degradation mechanism, and antitumor activity.

## Limitations

  • The paper notes that the precise mechanism of SH6 binding to SALL4 remains to be determined.
  • The authors state that future clinical studies are needed to confirm effectiveness and safety in humans.
  • Evident from the text: the in vivo efficacy data are from mouse xenograft and PDX models, not human trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s44321-025-00241-3

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY · PubMed Central
Image 2
CC BY · PubMed Central
Figure 1 Identification of a novel ZFC4 binding site. (A) Schematic representation of SALL4 protein isoforms. Dark blue rectangles = zinc fingers. SALL4A consists of four C2H2 zinc finger clusters (ZFC1, ZFC2, ZFC3, & ZFC4), while SALL4B, an internally spliced isoform, contains only ZFC1 and ZFC4. ZFC1 consists of Zinc Finger (ZNF) 1, ZFC2 consists of ZNF2&3, ZFC3 consists of ZNF4, 5, and 6, while ZFC4 consists of ZNF7&8. (B) Ligand Interaction Diagram of the SALL4 ZFC4-DNA complex is shown schematically. (i) Key SALL4 residues (N912) are labeled within red circles. Zinc ions are shown as small green circles. The duplex DNA strands are labeled arbitrarily with letters Y and X and numbered sequentially. Key interactions are shown as dotted red arrows. (ii) Alignment of our complex SALL4 structure (light blue) with recently deposited SALL4 complex structures 7Y3I (light orange) and 8A4I (cyan). (C) AlphaFold2 prediction of SALL4A and SALL4B. Left panel: ZNF1 (Green), ZNF2 (Cyan), ZNF3 (Teal), ZNF4 (magenta), ZNF5 (hot pink), ZNF6 (pink), ZNF7 (orange), and ZNF8 (wheat). Right panel: SALL4B, highlighted ZNF4 (ZNF7 (orange) and ZNF8 (wheat)). (D, E) Binding site prediction of SALL4 using SALL4 models from (A) and the ZFC4-DNA structure. Top view and side view of predicted binding sites on the SALL4A (D) and SALL4B (E) are shown. (F) Small-molecule docking screen against the common ZFC4 binding site in SALL4A (BS3) and SALL4B (BS1). Green = LOPAC1280 library, Orange = FDA approved anti-cancer library, Blue = SH library. Total number of compounds = 676. Shortlisted compounds (n = 119) with −5.0 cut off docking scores were highlighted in gray box, n = number of compounds. (G) The SH series of compounds are based on a hybrid design that incorporates the N-phenylpyridin-2-amino motif (rings A, B) of E7010 to the HDAC N-(2-aminophenyl) acrylamide moiety (ring C). (H) The following scaffolds are found in the SH series: B-1 in SH1-SH7, SH9-SH15, AH17-SH23, SH25-SH31, SH33-SH39 are characterized by an acrylamide linker D; B-2 is representative of SH41-SH47, SH49-SH55, SH57-SH63, SH65-SH71, SH73-SH79 in which linker E is an amide; B-3 are arylamides in which ring C is replaced by OH (SH8,SH16,SH24,SH32,SH40); B-4 are amides in which ring C is replaced by OH (SH48,SH56,SH64,SH72,SH80). Source data are available online for this figure.
Figure 1 Identification of a novel ZFC4 binding site. (A) Schematic representation of SALL4 protein isoforms. Dark blue rectangles = zinc fingers. SALL4A consists of four C2H2 zinc finger clusters (ZFC1, ZFC2, ZFC3, & ZFC4), while SALL4B, an internally spliced isoform, contains only ZFC1 and ZFC4. ZFC1 consists of Zinc Finger (ZNF) 1, ZFC2 consists of ZNF2&3, ZFC3 consists of ZNF4, 5, and 6, while ZFC4 consists of ZNF7&8. (B) Ligand Interaction Diagram of the SALL4 ZFC4-DNA complex is shown schematically. (i) Key SALL4 residues (N912) are labeled within red circles. Zinc ions are shown as small green circles. The duplex DNA strands are labeled arbitrarily with letters Y and X and numbered sequentially. Key interactions are shown as dotted red arrows. (ii) Alignment of our complex SALL4 structure (light blue) with recently deposited SALL4 complex structures 7Y3I (light orange) and 8A4I (cyan). (C) AlphaFold2 prediction of SALL4A and SALL4B. Left panel: ZNF1 (Green), ZNF2 (Cyan), ZNF3 (Teal), ZNF4 (magenta), ZNF5 (hot pink), ZNF6 (pink), ZNF7 (orange), and ZNF8 (wheat). Right panel: SALL4B, highlighted ZNF4 (ZNF7 (orange) and ZNF8 (wheat)). (D, E) Binding site prediction of SALL4 using SALL4 models from (A) and the ZFC4-DNA structure. Top view and side view of predicted binding sites on the SALL4A (D) and SALL4B (E) are shown. (F) Small-molecule docking screen against the common ZFC4 binding site in SALL4A (BS3) and SALL4B (BS1). Green = LOPAC1280 library, Orange = FDA approved anti-cancer library, Blue = SH library. Total number of compounds = 676. Shortlisted compounds (n = 119) with −5.0 cut off docking scores were highlighted in gray box, n = number of compounds. (G) The SH series of compounds are based on a hybrid design that incorporates the N-phenylpyridin-2-amino motif (rings A, B) of E7010 to the HDAC N-(2-aminophenyl) acrylamide moiety (ring C). (H) The following scaffolds are found in the SH series: B-1 in SH1-SH7, SH9-SH15, AH17-SH23, SH25-SH31, SH33-SH39 are characterized by an acrylamide linker D; B-2 is representative of SH41-SH47, SH49-SH55, SH57-SH63, SH65-SH71, SH73-SH79 in which linker E is an amide; B-3 are arylamides in which ring C is replaced by OH (SH8,SH16,SH24,SH32,SH40); B-4 are amides in which ring C is replaced by OH (SH48,SH56,SH64,SH72,SH80). Source data are available online for this figure.CC BY · PubMed Central
Figure EV1 Crystal Structure of the fourth SALL4 zinc finger cluster (ZFC4, teal and magenta) bound to DNA (yellow). The structural view (left) demonstrates how the two zinc fingers of the first SALL4 molecule (ZFC4b & ZFC4b’) and the second zinc finger of the second SALL4 molecule (ZFC4a) in the asymmetric unit bind in the major groove of DNA. Structural view in the box (right) depicting the specific interactions between N912 of SALL4 and adenines at position Y4, Y5, and X10 of DNA.
Figure EV1 Crystal Structure of the fourth SALL4 zinc finger cluster (ZFC4, teal and magenta) bound to DNA (yellow). The structural view (left) demonstrates how the two zinc fingers of the first SALL4 molecule (ZFC4b & ZFC4b’) and the second zinc finger of the second SALL4 molecule (ZFC4a) in the asymmetric unit bind in the major groove of DNA. Structural view in the box (right) depicting the specific interactions between N912 of SALL4 and adenines at position Y4, Y5, and X10 of DNA.CC BY · PubMed Central
Figure 2 Identification of a novel class of SALL4 inhibitor. (A) Single dose phenotypic screen using SALL4 high (SNU398) vs. low cell lines (SNU387) for 117 selected compounds from Fig. 1F, Datasets EV2, EV3; two of the compounds are not available for testing. (B) SH library compounds were tested for EC50 in cell viability assays. Isogenic cell lines specifically expressing SALL4A (SNU387-TgSALL4A) or SALL4B (SNU387-TgSALL4B) were tested alongside SNU398 and SNU387 cells. SH2, SH6, SH7, and SH61 are shown in the representative graphs. (C) SH6 was utilized in dose-dependent phenotypic screens using the SALL4 high lung cancer cell lines H661 and H838, as well as breast cancer line CAL51 (red) and SALL4 low lung cancer lines H1552 and H2030 (gray). (D) Schematic representation of three key structure-activity correlations in the SH library. A detailed description can be found in Fig. EV3. Each data point in (B) and (C) was performed in n = 3 independent cell cultures. IC50 of compounds was determined using nonlinear regression fitting, with error bars representing the s.d. of the mean. Source data are available online for this figure.
Figure 2 Identification of a novel class of SALL4 inhibitor. (A) Single dose phenotypic screen using SALL4 high (SNU398) vs. low cell lines (SNU387) for 117 selected compounds from Fig. 1F, Datasets EV2, EV3; two of the compounds are not available for testing. (B) SH library compounds were tested for EC50 in cell viability assays. Isogenic cell lines specifically expressing SALL4A (SNU387-TgSALL4A) or SALL4B (SNU387-TgSALL4B) were tested alongside SNU398 and SNU387 cells. SH2, SH6, SH7, and SH61 are shown in the representative graphs. (C) SH6 was utilized in dose-dependent phenotypic screens using the SALL4 high lung cancer cell lines H661 and H838, as well as breast cancer line CAL51 (red) and SALL4 low lung cancer lines H1552 and H2030 (gray). (D) Schematic representation of three key structure-activity correlations in the SH library. A detailed description can be found in Fig. EV3. Each data point in (B) and (C) was performed in n = 3 independent cell cultures. IC50 of compounds was determined using nonlinear regression fitting, with error bars representing the s.d. of the mean. Source data are available online for this figure.CC BY · PubMed Central
Figure EV3 Structural activity of SH library. Phenotypic screening of the SH library on SALL4 cell lines (Dataset EV4) revealed three key structure-activity correlations. First, the acrylamide linker D is an indispensable feature for activity. Replacing this linker with an amide resulted in compounds which have markedly lower activity against the SALL4 high cells. In fact, of the compounds with amide linkers (scaffold B-2, Fig. 1H), only four (SH43,47,69,71) have EC50 values ≤20 μM on SALL4 high cells, as compared to 31 out of 35 compounds in acrylamide bearing scaffold B-1. Unlike the amide, electron withdrawal by the carbonyl oxygen in the acrylamide linker delocalizes the positive charge onto the β carbon, resulting in more extensive distribution of charge in the acryan electron deficient β carbon which is susceptible to reaction with electron rich species. It is conceivable that this enhanced reactivity contributed to the greater cell-based potencies of the acrylamide-based SH compounds. A second requirement for potent activity is the ortho diamino motif E derived from the HDAC component in the hybrid scaffold. Of the two ortho-diamino groups, one is embedded within the acrylamide linker D while the other is a substituent on ring C. The ortho positioning of the amino groups is optimal for zinc binding. When Ring C is replaced by hydroxyl (OH) as seen in scaffold B-3 (SH8, SH16, SH24, SH32, SH40), activity was diminished, notwithstanding the retention of the zinc binding motif which is now represented by hydroxamic acid. The diminished activity is likely due to the absence of the sterically larger and bulkier ring C. Lastly, we noted that 6 of the 8 potent compounds (EC50 < 3 μM, all from scaffold B-1) have a trimethoxy substituted ring B. Rings A and B are part of the scaffold found in the antimicrotubule agent E7010, with ring B attached to the ortho position of pyridyl ring A. Mono-substitution of ring B with either methoxy, chloro, fluoro, or trifluoromethyl generally diminished activity. Possibly the sterically bulky and lipophilic trimethoxy substituted ring B has a role in reinforcing interactions with the putative receptor, hence contributing to enhanced potency.
Figure EV3 Structural activity of SH library. Phenotypic screening of the SH library on SALL4 cell lines (Dataset EV4) revealed three key structure-activity correlations. First, the acrylamide linker D is an indispensable feature for activity. Replacing this linker with an amide resulted in compounds which have markedly lower activity against the SALL4 high cells. In fact, of the compounds with amide linkers (scaffold B-2, Fig. 1H), only four (SH43,47,69,71) have EC50 values ≤20 μM on SALL4 high cells, as compared to 31 out of 35 compounds in acrylamide bearing scaffold B-1. Unlike the amide, electron withdrawal by the carbonyl oxygen in the acrylamide linker delocalizes the positive charge onto the β carbon, resulting in more extensive distribution of charge in the acryan electron deficient β carbon which is susceptible to reaction with electron rich species. It is conceivable that this enhanced reactivity contributed to the greater cell-based potencies of the acrylamide-based SH compounds. A second requirement for potent activity is the ortho diamino motif E derived from the HDAC component in the hybrid scaffold. Of the two ortho-diamino groups, one is embedded within the acrylamide linker D while the other is a substituent on ring C. The ortho positioning of the amino groups is optimal for zinc binding. When Ring C is replaced by hydroxyl (OH) as seen in scaffold B-3 (SH8, SH16, SH24, SH32, SH40), activity was diminished, notwithstanding the retention of the zinc binding motif which is now represented by hydroxamic acid. The diminished activity is likely due to the absence of the sterically larger and bulkier ring C. Lastly, we noted that 6 of the 8 potent compounds (EC50 < 3 μM, all from scaffold B-1) have a trimethoxy substituted ring B. Rings A and B are part of the scaffold found in the antimicrotubule agent E7010, with ring B attached to the ortho position of pyridyl ring A. Mono-substitution of ring B with either methoxy, chloro, fluoro, or trifluoromethyl generally diminished activity. Possibly the sterically bulky and lipophilic trimethoxy substituted ring B has a role in reinforcing interactions with the putative receptor, hence contributing to enhanced potency.CC BY · PubMed Central
Figure EV2 Structures and physicochemical properties of potent analogs SH2, SH6, and SH7. (A) These compounds have the lowest EC50 values (<3 μM) on SALL4 high SNU 398 cells. (B) Permeability test (PAMPA) result of the negative control (Antipyrine) and positive control (Carbamazepine).
Figure EV2 Structures and physicochemical properties of potent analogs SH2, SH6, and SH7. (A) These compounds have the lowest EC50 values (<3 μM) on SALL4 high SNU 398 cells. (B) Permeability test (PAMPA) result of the negative control (Antipyrine) and positive control (Carbamazepine).CC BY · PubMed Central
Figure 3 IMiD independent SH6-mediated CUL4A-CRBN degradation of SALL4. (A) SNU398 cells were treated with pomalidomide or SH6 at the indicated concentrations for 24 h. Cells were harvested for western blot analysis. (B) Cells were treated with SH6 or lenalidomide for 72 h and examined for their viability. SH6 decreases cell viability while Lenalidomide does not show activity on these cells. (C) Dual-luciferase reporter assay. SALL4B was fused to the NanoLuc dual luciferase vector (pLL3.7-EF1a-IRES-Gateway-nluc-2xHA-IRES2-fluc-hCL1-P2A-Puro) and stably transfected into SALL4 + H1299 lung cancer cells. Cells were treated with SH6 or lenalidomide for 24 h and assayed for luminescence. DMSO normalized NLuc/FLuc data was presented as the mean ± s.d. of n = 3 biologically independent samples. (D) DMSO, MLN4924 (MLN), MG132 (MG), Thalidomide (Thal), zVAD-FMK (zVAD), or Chloroquine (CQ) were added for four hours prior to SH6 treatment, followed by western blot analysis 24 h later. MLN4924 and MG132 demonstrated prominent rescue of SH6 degradation of SALL4 (red arrows). Experiments were performed twice with independent cell cultures. (E) MLN4924 rescue of SH6 induced cell killing. SNU398 cells were incubated with SH6 or SH6 in combination with MLN4924 (SH6 + MN) for 24 h, 48 h, or 72 h. Cell viability was measured and data are presented as mean ± s.d. of n = 3 biologically independent samples. (F) Cells were incubated with SH6 for 4 h prior to CETSA analysis of the Cullin pathway. In-cell CETSA was performed as described in Materials and Methods. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting. In-cell CETSA demonstrated that SH6 prolongs thermal stability for CUL4A, CRBN, and SALL4, in comparison to DMSO. (G) Cells treated with Thalidomide or DMSO underwent in-cell CETSA, revealing that Thalidomide stabilizes CRBN but not CUL4A. Each data point in (B), (C) and (E) was perform in n = 3 independent cell cultures. Inhibition curves were determined using nonlinear regression fitting, with error bars represents s.d. of mean. Source data are available online for this figure.
Figure 3 IMiD independent SH6-mediated CUL4A-CRBN degradation of SALL4. (A) SNU398 cells were treated with pomalidomide or SH6 at the indicated concentrations for 24 h. Cells were harvested for western blot analysis. (B) Cells were treated with SH6 or lenalidomide for 72 h and examined for their viability. SH6 decreases cell viability while Lenalidomide does not show activity on these cells. (C) Dual-luciferase reporter assay. SALL4B was fused to the NanoLuc dual luciferase vector (pLL3.7-EF1a-IRES-Gateway-nluc-2xHA-IRES2-fluc-hCL1-P2A-Puro) and stably transfected into SALL4 + H1299 lung cancer cells. Cells were treated with SH6 or lenalidomide for 24 h and assayed for luminescence. DMSO normalized NLuc/FLuc data was presented as the mean ± s.d. of n = 3 biologically independent samples. (D) DMSO, MLN4924 (MLN), MG132 (MG), Thalidomide (Thal), zVAD-FMK (zVAD), or Chloroquine (CQ) were added for four hours prior to SH6 treatment, followed by western blot analysis 24 h later. MLN4924 and MG132 demonstrated prominent rescue of SH6 degradation of SALL4 (red arrows). Experiments were performed twice with independent cell cultures. (E) MLN4924 rescue of SH6 induced cell killing. SNU398 cells were incubated with SH6 or SH6 in combination with MLN4924 (SH6 + MN) for 24 h, 48 h, or 72 h. Cell viability was measured and data are presented as mean ± s.d. of n = 3 biologically independent samples. (F) Cells were incubated with SH6 for 4 h prior to CETSA analysis of the Cullin pathway. In-cell CETSA was performed as described in Materials and Methods. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting. In-cell CETSA demonstrated that SH6 prolongs thermal stability for CUL4A, CRBN, and SALL4, in comparison to DMSO. (G) Cells treated with Thalidomide or DMSO underwent in-cell CETSA, revealing that Thalidomide stabilizes CRBN but not CUL4A. Each data point in (B), (C) and (E) was perform in n = 3 independent cell cultures. Inhibition curves were determined using nonlinear regression fitting, with error bars represents s.d. of mean. Source data are available online for this figure.CC BY · PubMed Central
Figure EV4 The structural model of SALL4A recruited to the CRBN-DDB1-CUL4A-Rbx1 complex. (A) ZFC2-4 was predicted to bind to CUL4A near the Rbx1 site. (i) Superimposed 3D structures of the SALL4A ZnF3-CRBN-DDB1(green) complex (PDB ID: 6UML) and DDB1(yellow)-CUL4A-Rbx1 complex (PDB ID: 2HYE) with reference to DDB1. (ii) Cartoon illustration of the SALL4A/B-CRBN-DDB1-CUL4A-RbX1 protein interaction network. (iii) Superimposed 3D structures of the SALL4A ZnF3-CRBN-DDB1(green) complex (PDB ID: 6UML) and DDB1(yellow)-CUL4A-Rbx1-ZFC 2–4 of the SALL4A complex (generated by protein–protein docking) with reference to the DDB1 domain. (B) The docking pose of SH6 at the predicted SALL4B ZFC4-CUL4A interface. Wheat and orange = SALL4B ZFC4; Cyan = CUL4A.
Figure EV4 The structural model of SALL4A recruited to the CRBN-DDB1-CUL4A-Rbx1 complex. (A) ZFC2-4 was predicted to bind to CUL4A near the Rbx1 site. (i) Superimposed 3D structures of the SALL4A ZnF3-CRBN-DDB1(green) complex (PDB ID: 6UML) and DDB1(yellow)-CUL4A-Rbx1 complex (PDB ID: 2HYE) with reference to DDB1. (ii) Cartoon illustration of the SALL4A/B-CRBN-DDB1-CUL4A-RbX1 protein interaction network. (iii) Superimposed 3D structures of the SALL4A ZnF3-CRBN-DDB1(green) complex (PDB ID: 6UML) and DDB1(yellow)-CUL4A-Rbx1-ZFC 2–4 of the SALL4A complex (generated by protein–protein docking) with reference to the DDB1 domain. (B) The docking pose of SH6 at the predicted SALL4B ZFC4-CUL4A interface. Wheat and orange = SALL4B ZFC4; Cyan = CUL4A.CC BY · PubMed Central
Figure 4 SH6 is a C2H2 ZFC4 degrader. (A) 293T cells were stably transfected with pFUW-SALL4B wild type (SALL4BWT), or pFUW-SALL4B with deletion of ZFC4 (SALL4B-ZFC4). Cells were treated with SH6, lenalidomide (Len), or DMSO for 24 h before harvested for western blot analysis. SH6-mediated degradation of SALL4B was abolished in the absence of ZFC4, while lenalidomide did not affect SALL4B levels in SALL4B-ZFC4 or SALL4BWT cells. (B) Co-Immunoprecipitation pull down assay showing interaction of SALL4B and SH6. 293T SALL4BWT or SALL4B-ZFC4 cells were treated with 2.5 μM biotinylated SH6 for 2 h, and bound proteins were eluted for western blot analysis. The assays demonstrated that SALL4B was bound and pulled down by biotinylated SH6 in SALL4BWT cells, but not in SALL4B-ZFC4 cells. (C) 293T SALL4BWT or SALL4B-ZFC4 cells were incubated with SH6 for 4 h prior to CETSA analysis. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting for CUL4A and SALL4. The result demonstrated that SH6 prolonged thermal stability for CUL4A in both cell types ((i) and (ii)). SH6 also prolonged SALL4B stability in 293T SALL4BWT cells (iii), but not in SALL4B-ZFC4 cells (iv), indicating no binding of SH6 to SALL4B without ZFC4. Red box highlighted the difference of the proteins under SH6 or DMSO treatment. (D) Proteomic study on SH6 treated SNU398 cells. A volcano plot from the mass spectrometry data demonstrating the change of the cellular proteins from the SH6 vs DMSO treatment. Downregulated proteins with twofold change and p-value of 0.05 were highlighted in red. (E) Sequence alignment of the SALL4 ZFC4 domain with ZFP91 and ZNF653. α-helices (α) and β-strands (β) are indicated according to data on crystal structures of SALL4 ZFC4. The color scheme used for residue conservation is based on side chain properties. Blue = positive charge (K, R, H); Cyan = polar (S, T, N, Q); Green=hydrophobic (A, I, L, M, V, G); Yellow = cysteine (C); Pink = negative (D, E); Orange = aromatic (F, Y, W). gray = proline (P). Source data are available online for this figure.
Figure 4 SH6 is a C2H2 ZFC4 degrader. (A) 293T cells were stably transfected with pFUW-SALL4B wild type (SALL4BWT), or pFUW-SALL4B with deletion of ZFC4 (SALL4B-ZFC4). Cells were treated with SH6, lenalidomide (Len), or DMSO for 24 h before harvested for western blot analysis. SH6-mediated degradation of SALL4B was abolished in the absence of ZFC4, while lenalidomide did not affect SALL4B levels in SALL4B-ZFC4 or SALL4BWT cells. (B) Co-Immunoprecipitation pull down assay showing interaction of SALL4B and SH6. 293T SALL4BWT or SALL4B-ZFC4 cells were treated with 2.5 μM biotinylated SH6 for 2 h, and bound proteins were eluted for western blot analysis. The assays demonstrated that SALL4B was bound and pulled down by biotinylated SH6 in SALL4BWT cells, but not in SALL4B-ZFC4 cells. (C) 293T SALL4BWT or SALL4B-ZFC4 cells were incubated with SH6 for 4 h prior to CETSA analysis. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting for CUL4A and SALL4. The result demonstrated that SH6 prolonged thermal stability for CUL4A in both cell types ((i) and (ii)). SH6 also prolonged SALL4B stability in 293T SALL4BWT cells (iii), but not in SALL4B-ZFC4 cells (iv), indicating no binding of SH6 to SALL4B without ZFC4. Red box highlighted the difference of the proteins under SH6 or DMSO treatment. (D) Proteomic study on SH6 treated SNU398 cells. A volcano plot from the mass spectrometry data demonstrating the change of the cellular proteins from the SH6 vs DMSO treatment. Downregulated proteins with twofold change and p-value of 0.05 were highlighted in red. (E) Sequence alignment of the SALL4 ZFC4 domain with ZFP91 and ZNF653. α-helices (α) and β-strands (β) are indicated according to data on crystal structures of SALL4 ZFC4. The color scheme used for residue conservation is based on side chain properties. Blue = positive charge (K, R, H); Cyan = polar (S, T, N, Q); Green=hydrophobic (A, I, L, M, V, G); Yellow = cysteine (C); Pink = negative (D, E); Orange = aromatic (F, Y, W). gray = proline (P). Source data are available online for this figure.CC BY · PubMed Central
Figure 5 SH6 leads to tumor regression and demonstrates a satisfactory pharmacokinetic profile. (A) SH6 specifically inhibits cell growth of SNU398 HCC but not non-transformed liver cell lines THLE-2 and THLE-3. (B) Mouse xenograft experiments. NSG mice were transplanted with 2 × 106 SNU398 cells, and the tumors were allowed to form a palpable mass. 20 mg/kg SH6 (n = 20), 40 mg/kg SH6 (n = 13) or vehicle control (n = 20) was administered every other day from Day 7 to Day 17. Tumors of the harvested xenografts at Day 17. Tumor weight (B (i)) and body weight of mice (B (ii)) were measured at end point. n.s. = not significant. P values were calculated by the two-tailed Student’s t-test. Error bars = standard error of the mean (SEM). (C) (i) Patient-derived Xenograft (PDX) study design. Mice receiving PDX were randomly grouped and treated with vehicle control (n = 13) or 50 mg/kg SH6 (n = 13), n = number of mice. Tumors harvested at end point were photographed C(ii). Four of the representative tumors from each treatment group were analyzed for SALL4 protein expression using western blot C(iii). Tumor growth was measured and traced (n = 13 for each group) (iv), and tumor volume measured at endpoint (n = 13 for each group). N = number of mice (v). P values were calculated by the two-tailed Student’s t-test. Error bars = standard error of the mean (SEM). Body weight of mice were also traced (vi) and measured at endpoint (vii). (D) Body weight of four healthy FVB/NJ mice receiving 50 mg/kg SH6 daily for 10 days. The plot represents the distribution of body weights across SH6 treated mice. The central line within each box corresponds to the median (50th percentile) body weight. The lower and upper bounds of the box represent the 25th (Q1) and 75th (Q3) percentiles, respectively, defining the interquartile range (IQR). Whiskers extend from the 25th percentile to the minimum value and from the 75th percentile to the maximum value, excluding any outliers. Error bars represent the standard error of the mean (SEM). All data are presented in grams (g). (E) Microsomal stability assay with 1 μM of SH6 or Verapamil. The percentage of the remaining compound (% Remaining, Y axis) was analyzed with LC-MS/MS. (F) Concentration response of hERG inhibition by SH6, with amitriptyline as the control. (G) Single dose pharmacokinetic study of SH6 via intravenous injection (5 mg/kg) or oral gavage (15 mg/kg) on Swiss albino mice (n = 3). The plasma concentration of the compound was measured with LC-MS/MS. Each data point in (A), (E), (F) and (G) was performed in n = 3 independent cell cultures. IC50 of compounds in (A), (F) and (G) were determined using nonlinear regression fitting, with error bars representing the standard deviation of the mean. P values were calculated by the two-tailed Student’s t-test. Source data are available online for this figure.
Figure 5 SH6 leads to tumor regression and demonstrates a satisfactory pharmacokinetic profile. (A) SH6 specifically inhibits cell growth of SNU398 HCC but not non-transformed liver cell lines THLE-2 and THLE-3. (B) Mouse xenograft experiments. NSG mice were transplanted with 2 × 106 SNU398 cells, and the tumors were allowed to form a palpable mass. 20 mg/kg SH6 (n = 20), 40 mg/kg SH6 (n = 13) or vehicle control (n = 20) was administered every other day from Day 7 to Day 17. Tumors of the harvested xenografts at Day 17. Tumor weight (B (i)) and body weight of mice (B (ii)) were measured at end point. n.s. = not significant. P values were calculated by the two-tailed Student’s t-test. Error bars = standard error of the mean (SEM). (C) (i) Patient-derived Xenograft (PDX) study design. Mice receiving PDX were randomly grouped and treated with vehicle control (n = 13) or 50 mg/kg SH6 (n = 13), n = number of mice. Tumors harvested at end point were photographed C(ii). Four of the representative tumors from each treatment group were analyzed for SALL4 protein expression using western blot C(iii). Tumor growth was measured and traced (n = 13 for each group) (iv), and tumor volume measured at endpoint (n = 13 for each group). N = number of mice (v). P values were calculated by the two-tailed Student’s t-test. Error bars = standard error of the mean (SEM). Body weight of mice were also traced (vi) and measured at endpoint (vii). (D) Body weight of four healthy FVB/NJ mice receiving 50 mg/kg SH6 daily for 10 days. The plot represents the distribution of body weights across SH6 treated mice. The central line within each box corresponds to the median (50th percentile) body weight. The lower and upper bounds of the box represent the 25th (Q1) and 75th (Q3) percentiles, respectively, defining the interquartile range (IQR). Whiskers extend from the 25th percentile to the minimum value and from the 75th percentile to the maximum value, excluding any outliers. Error bars represent the standard error of the mean (SEM). All data are presented in grams (g). (E) Microsomal stability assay with 1 μM of SH6 or Verapamil. The percentage of the remaining compound (% Remaining, Y axis) was analyzed with LC-MS/MS. (F) Concentration response of hERG inhibition by SH6, with amitriptyline as the control. (G) Single dose pharmacokinetic study of SH6 via intravenous injection (5 mg/kg) or oral gavage (15 mg/kg) on Swiss albino mice (n = 3). The plasma concentration of the compound was measured with LC-MS/MS. Each data point in (A), (E), (F) and (G) was performed in n = 3 independent cell cultures. IC50 of compounds in (A), (F) and (G) were determined using nonlinear regression fitting, with error bars representing the standard deviation of the mean. P values were calculated by the two-tailed Student’s t-test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV5 Western blot analysis of SALL4 protein expression of patient samples. The PDX used in xenograph studies was established from patient 3 with a high level of SALL4 expression. Normal represents adjacent patient sample which did not express detectable levels of SALL4.
Figure EV5 Western blot analysis of SALL4 protein expression of patient samples. The PDX used in xenograph studies was established from patient 3 with a high level of SALL4 expression. Normal represents adjacent patient sample which did not express detectable levels of SALL4.CC BY · PubMed Central
Image 13
CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 0 Not valid · 7 Not checked · 59 Own results and interpretations

30 more claims · 2 with their cited sources checked

Create a free account to see all 80 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 16
  • The quote only partly states this claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 8

Metadata

Authors
Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., Kwon, J., Seo, H.-S., Song, K., Tian, X., Feng, L., Tan, J. L., Melkonian, A. V., Liu, Z., Wulf, G., Arthanari, H., Qi, J., Dhe-Paganon, S., Clohessy, J. G., Choong, Y. K., Sivaraman, J., Fan, H., Tenen, D. G., & Chai, L.
Affiliations
  • Cancer Science Institute of Singapore (SG)
  • Brigham and Women's Hospital (US)
  • Agency for Science, Technology and Research (SG)
  • National University of Singapore (SG)
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • Shenzhen Bay Laboratory (CN)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
  • Liu, Bee Hui
  • Liu, Miao
  • Jaladanki, Chaitanya Kumar
  • Gao, Chong
Venue
EMBO Molecular Medicine
Published
2025-05-14
Volume
17
Issue
6
Pages
1393-1416
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4410364266
Cited by
8
References
47
Citations by year
2026: 3 · 2025: 5
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders
  • Ministry of Health -Singapore (STaR18nov-0002)
  • Ministry of Education - Singapore
  • National Research Foundation, Singapore (CIRG21nov-0009CIRG21nov-0009)
  • Foundation for the National Institutes of Health (P01HL131477-01A1, P01 HL158688/HL/NHLBI NIH, P30 GM124165, S10OD021527)
  • DOE | SC | Argonne National Laboratory
  • Xiu Research Fund
  • Linde Family Foundation
  • AGA/Jenzabar Research Fund
  • Breast Cancer Research Foundation BCRF (24-177)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
SALL4, C2H2 zinc finger transcription factor, protein degradation, small molecule inhibitors, patient-derived xenografts, tumor growth inhibition, pharmacokinetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting transcription factors through an IMiD independent zinc finger domain. https://app.cochat.ai/papers/10.1038/s44321-025-00241-3
The paper
Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., Kwon, J., Seo, H.-S., Song, K., Tian, X., Feng, L., Tan, J. L., Melkonian, A. V., Liu, Z., Wulf, G., . . . Chai, L. (2025). Targeting transcription factors through an IMiD independent zinc finger domain. EMBO Molecular Medicine. https://doi.org/10.1038/s44321-025-00241-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.